Nicholas Benedict

Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd.

Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany.

Archimedes Pharma Ltd. operates as a holding company with interests in pharmaceuticals. The company was founded by Richard Anthony de Souza, Charles Marchetti and Michael Clark on December 9, 2004 and is headquartered in London, the United Kingdom.

Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY.

Lumavita AG is a specialty biopharmaceutical company dedicated to bring to market innovative anti-infectives for women's health. Based in Basel, Switzerland, Lumavita was recently financed by a syndicate, lead by Atlas Venture, with CHF18 million (EUR11 million). The company has one product under regulatory review in Switzerland and two further projects in clinical development.